EXHIBIT 354

Case: 1:17-md-02804-DAP Doc #: 1965-36 Filed: 07/23/19 2 of 4. PageID #: 167375 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Highly Confidential - Subject to Further Confidentiality Review

Page 162 Page 164 Q. So, all within a matter of approximately 1 1 paragraph. 2 2 14 months, 15 months? Would you just compare. Generally 3 3 Exhibits 7 and 8 appear to be very similar or A. Yes. almost identical. Q. And, again, the second sentence of 9, 4 4 5 5 Exhibit 9, says, "The purpose of this letter is to A. Yes, they appear to be -- from what I б can tell, yeah, they look pretty similar. 6 reiterate the responsibilities of controlled 7 7 substance manufacturers and distributors to inform Q. Again, I know you didn't have time to 8 review every single word but they're very similar, 8 DEA of suspicious orders in accordance with 21 9 correct? 9 CFR." 10 10 A. They look similar. Correct? 11 11 A. I'm sorry. I lost you on that. Where Q. So, now, sir, as part of or chief director of internal audit at Walgreens, do you 12 12 are you at? 13 recall seeing this February 7, 2007 letter as part 13 Q. The second sentence of the first 14 of the -- your group's internal audit of the 14 paragraph. 15 distribution centers? 15 A. First paragraph. Okay. 16 A. I don't recall seeing this document. 16 "The purpose of this letter is to 17 17 reiterate the responsibilities of controlled Just to make sure I'm not missing 18 something, you don't recall in the last two 18 substance manufacturers and distributors to inform 19 exhibits, 7 and 8, seeing any synopsis or bullets 19 DEA of suspicious orders in accordance with 21 CFR 20 or anything that captures the content in Exhibits 7 20 1301.74(b)." 21 or 8 when performing the audit, correct? 21 Correct? 22 22 A. Yes. A. I certainly don't recall that, no. 23 Q. All right. Let me hand you what I will 23 Q. Now, just to quickly look over --24 mark as Domzalski 9. 24 quickly review this document. Page 163 Page 165 1 (WHEREUPON, a certain document was 1 The second paragraph, do you see the 2 2 marked as Walgreens-Domzalski second sentence indicates that DEA regs require all 3 Exhibit No. 9: 12/27/07 letter 3 distributors to report suspicious orders of 4 from U.S. DOJ DEA; MCKMDL00478910 -4 controlled substances, right? 5 5 00478911.) A. Yes. б BY MR. MOUGEY: 6 Q. And I'm assuming the answer to this next 7 Q. Do you see the date on this, sir, 7 question is the same as before, that you can't December 27, 2007? 8 discern from the internal audit report whether your 8 9 A. Yes, I do. 9 group's audit covered Walgreens' responsibility to 10 Q. And we've now -- the first sentence, 10 identify suspicious orders, right? "This letter is being sent to every entity in the 11 11 A. No, I cannot recall that. 12 United States registered with the Drug Enforcement 12 Q. And --13 Administration to manufacture or distribute 13 A. Cannot identify it from the report. 14 controlled substances." 14 Q. You'll see here -- let's go down to the 15 Correct? 15 third paragraph. 16 A. Yes. A. Yes. 16 17 Q. And your understanding is, again, that 17 Q. "The regulation also requires the would include Walgreens? registrant inform the local DEA Division Office of 18 18 19 A. Yes. 19 suspicious orders when discovered by the 20 Q. So, we've now seen correspondence from 20 registrant." 21 the U.S. Department of Justice DEA from 21 Sir, is it safe to conclude that you 22 September 27, 2006, February 7, 2007 and then a 22 can't tell from looking at this internal audit, 23 third letter, December 27, 2007, correct, sir? 23 meaning Exhibit 3, whether or not the excessive 24 24 Yes. purchase reports or suspicious order reports were